Osimertinib Has Transformed Lung Cancer Care — But at What Cost to the Heart?
Muhammad Awidi, Hematology and Oncology Fellow at Roswell Park Cancer Center, shared on LinkedIn.
”Osimertinib has changed the landscape for EGFR-mutated lung cancer, but its long-term heart safety has remained uncertain.
In our latest paper, we found that patients treated with osimertinib had higher rates of cardiomyopathy, ischemic heart disease, and heart failure compared with earlier-generation EGFR inhibitors. As survival improves, our findings highlight the need for ongoing cardiovascular monitoring to help prevent late toxicities.
Grateful to my outstanding co-authors Zaid Muhanna, Muntaser Zyoud, and Ahmad Issa three talented medical students I had the privilege to mentor on this project.”
Read the full Abstract here.
Stay updated with Hemostasis Today.
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A
-
Aug 12, 2026, 05:47Shehab Mohamed: Philadelphia Negative MPNs in AYA vs Older Adults in Qatar
-
Aug 12, 2026, 05:35Burjor Langdana: Why Does Blast Traumatised Facial Tissue Keep Swelling and often Heal Badly